Press releases

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2018 on Wednesday, October...

Today, Boston Scientific (NYSE: BSX) announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA) application to market the Eluvia™ Drug-Eluting Vascular...

Today, Boston Scientific (NYSE: BSX) announced positive 12-month data from the IMPERIAL trial, the first head-to-head drug-eluting stent trial in the superficial femoral artery (SFA). Results were...

Boston Scientific Corporation (NYSE: BSX) today announced the global launch of the LithoVue Empower™ Retrieval Deployment Device, designed to be used with the LithoVue™ Single-Use Digital...

Boston Scientific Corporation (NYSE: BSX) today announced key data that will be presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the...

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Augmenix, Inc., a privately-held company which has developed and commercialized the...

Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018 in New York City. Mike Mahoney, chairman...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 13th Annual Wells Fargo Securities Healthcare Conference on Wednesday, September 5, 2018 in Boston. Susie Lisa, vice...

Boston Scientific Corporation (NYSE: BSX) today announced it has signed an agreement to acquire VENITI, Inc., a privately-held company in Fremont, California which has developed and commercialized...

Boston Scientific Corporation (NYSE: BSX) announced it has recently closed its acquisition of Claret Medical, Inc., a privately-held company that has developed and commercialized the Sentinel®...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 38th Annual Canaccord Genuity Growth Conference on Wednesday, August 8, 2018 in Boston. Susie Lisa, vice president,...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.490 billion during the second quarter ended June 30, 2018. This represents growth of 10.3 percent on a reported basis, 8.6 percent...

Boston Scientific Corporation (NYSE: BSX) has been notified of an unsolicited "mini-tender" offer by TRC Capital Corporation (TRC) to purchase up to three million shares of Boston Scientific's...

Boston Scientific Corporation (NYSE: BSX) today announced it has signed an agreement to acquire Claret Medical, Inc., a privately-held company that has developed and commercialized the Sentinel®...

Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Cryterion Medical, Inc., a privately-held company developing a single-shot cryoablation platform for the...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2018 on Wednesday, July 25,...

Boston Scientific (NYSE: BSX) today announced key data that will be presented at Digestive Disease Week (DDW) being held in Washington D.C., June 2 to June 5. The annual meeting is the largest...

Boston Scientific Corporation (NYSE: BSX) today announced the schedule of key presentations, including two late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 34th Annual Strategic Decisions Conference on May 31, 2018 in New York. Mike Mahoney, chairman and chief executive...

The CBS network television show “60 Minutes” recently aired an investigative story with completely false claims that suggested that our transvaginal mesh products contain counterfeited and smuggled materials. We want you to know the facts and understand our perspective.

Boston Scientific (NYSE: BSX) today announced results from an analysis of the LATITUDE database which evaluated the successful reduction of inappropriate shocks using the SMART Pass sensing filter...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2018 Health Care Conference on May 16, 2018 in Las Vegas. Dan Brennan, executive vice...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of NxThera. The company developed the Rezūm® system, a minimally invasive therapy (MIT) for patients with...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.379 billion during the first quarter ended March 31, 2018. This represents growth of 10.1 percent on a reported basis, 6.2 percent...

Boston Scientific Corporation (NYSE: BSX) today announced one-year data from the INTREPID study, the first and only prospective, double-blind, randomized, sham-controlled, multi-center study of...

Boston Scientific Corporation (NYSE: BSX) today announced that it, along with several other opponents, successfully opposed Edwards Lifesciences Corporation's European patent EP 2,399,550 ('550)...

Boston Scientific (NYSE: BSX) today announced that it has acquired nVision Medical Corporation, a privately-held company focused on women's health. nVision developed the first and only device...

Boston Scientific Corporation (NYSE: BSX) today announced the acquisition of Securus Medical Group, Inc., a privately-held company that has developed a thermal monitoring system for the continuous...

Boston Scientific Corporation (NYSE: BSX) today announced the U.K. Court of Appeal dismissed Edwards Lifesciences' appeal and upheld a prior court decision that Edwards' Sapien 3™ device...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2018 on Wednesday, April 25,...

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire NxThera, a privately-held company based in Maple Grove, Minnesota. NxThera developed and...

Boston Scientific Corporation (NYSE: BSX) announced real-world data from the TRUE-HD study during a late-breaking clinical trial session today at the annual congress of the European Heart Rhythm...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 in New York City. Susie Lisa, vice president,...

Boston Scientific Corporation (NYSE: BSX) today announced key data presentations that will be featured at the annual congress of the European Heart Rhythm Association (EHRA) in Barcelona, Spain,...

Boston Scientific Corporation (NYSE: BSX) will participate in the Barclays Global Healthcare Conference on March 13 in Miami Beach, Florida. Dan Brennan, executive vice president and chief...

Boston Scientific (NYSE: BSX) today announced that it has acquired EMcision, Limited, a privately held company located in the United Kingdom and Canada. The acquisition will expand the Boston...

Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.0 billion aggregate principal amount of its 4.000% senior notes due March 1, 2028. The Company previously announced that...

Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $1.0 billion aggregate principal amount of its 4.000% senior notes due March 1, 2028 under the company's...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.408 billion during the fourth quarter ended December 31, 2017. This represents growth of 9.9 percent on a reported basis and 8.1...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the LEERINK Partners 7th Annual Global Healthcare Conference on February 15, 2018 in New York. Dan Brennan, executive vice...

Boston Scientific commends the efforts of key champions in the U.S. House and Senate for their successful efforts to suspend the medical device tax, allowing the device industry to reinvest in...

Boston Scientific Corporation (NYSE: BSX) today announced it has closed an investment and entered into an acquisition option agreement with Millipede, Inc., a privately-held company that has...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2017 on Thursday, February...

Boston Scientific Corporation (NYSE: BSX) today announced positive results from the WHISPER randomized controlled trial (RCT). The data, presented at the 2018 Annual Meeting of the North American...

Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Spectra WaveWriter™ Spinal Cord Stimulator (SCS) System. It is the...

Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.41 billion during the fourth quarter ended December 31, 2017....

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 36th annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 in San Francisco, CA. Mike Mahoney, chairman...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, January 4, 2018 in Boston, MA. Mike Mahoney, chairman...

Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the Vercise™ Deep Brain Stimulation (DBS) System. DBS...

Boston Scientific Corporation (NYSE: BSX) will participate in the BMO Capital Markets Prescriptions for Success Healthcare Conference on December 14, 2017 in New York. Susie Lisa, vice president,...

Boston Scientific (NYSE: BSX) announces a delay to previously communicated timelines for commercialization of the LOTUS Edge™ Aortic Valve System* in Europe and the U.S. After initiating a...

Boston Scientific Corporation (NYSE: BSX) will participate in the Citi 2017 Global Healthcare Conference on December 7, 2017 in New York. Kevin Ballinger, executive vice president and president,...

Boston Scientific Corporation (NYSE: BSX) will participate in the Piper Jaffray 29th Annual Healthcare Conference on November 28, 2017 in New York. Susie Lisa, vice president, investor relations...

Updated guidelines issued by the American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Rhythm Society (HRS) now formally recommend the use of a subcutaneous...

Boston Scientific Corporation (NYSE: BSX) will participate in the Stifel 2017 Healthcare Conference on November 14, 2017 in New York. Dan Brennan, executive vice president and chief financial...

Boston Scientific Corporation (NYSE: BSX) will participate in the 26th Annual Credit Suisse Healthcare Conference on November 7, 2017 in Scottsdale, Arizona. Joe Fitzgerald, executive vice...

Boston Scientific (NYSE: BSX) announced final five-year outcomes data from the PREVAIL study of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device today during a late-breaking clinical...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.222 billion during the third quarter ended September 30, 2017. This represents growth of 5.6 percent on a reported basis and 5.7...

Boston Scientific (NYSE: BSX) today announced key data that will be presented at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular...

Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Desiree Ralls-Morrison as senior vice president, general counsel and corporate secretary. Ralls-Morrison will join...

Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Apama Medical Inc., a privately-held company that is developing the Apama Radiofrequency (RF) Balloon...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2017 on Thursday, October...

Boston Scientific (NYSE: BSX) has launched the Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring the...

Boston Scientific (NYSE: BSX) today announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study evaluating the performance of the...

Boston Scientific (NYSE: BSX) today announced results from a three year follow-up cohort in its Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma...

Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley Global Healthcare Conference on September 12, 2017 in New York City. Mike Mahoney, chairman and chief executive...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo Healthcare Conference on September 7, 2017 in Boston. Susie Lisa, vice president, Investor Relations, will...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Canaccord Genuity Growth Conference on August 9, 2017 in Boston. Boston Scientific investor relations representatives,...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.257 billion during the second quarter ended June 30, 2017. This represents growth of 6 percent on a reported basis and 7 percent on...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2017 on Thursday, July 27, 2017 at

Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to provide an overview of its business and long-term growth strategies. Chairman...

Boston Scientific (NYSE: BSX) has received CE mark for the Vercise™ Gevia™ Deep Brain Stimulation (DBS) System*, a rechargeable, magnetic resonance (MR) conditional device indicated for the...

Boston Scientific (NYSE: BSX) today announced positive results from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study evaluating...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2017 UBS Global Healthcare Conference on Tuesday, May 23, 2017 in New York City. Susie Lisa, vice president, investor...

Boston Scientific (NYSE: BSX) today announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris. Data from the study demonstrated...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter...

Boston Scientific (NYSE: BSX) today announced positive safety and efficacy rates of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry presented during a...

New analyses from the Boston Scientific Corporation (NYSE: BSX) sponsored PLATINUM Diversity study underscore the need for greater understanding of the clinical and nonclinical barriers that can...

Boston Scientific (NYSE: BSX) today announced results from the U.S. post-market approval study evaluating 'real-world' patients implanted with the Subcutaneous Implantable Defibrillator (S-ICD)...

Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including four late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific Program,...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization...

Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including two late-breaking clinical trials, that will be featured at the 38th Annual Scientific Sessions of...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2017 Healthcare Conference on Thursday, May 18, 2017 in Las Vegas. Susie Lisa, vice...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.160 billion during the first quarter ended March 31, 2017. This represents growth of 10 percent compared to the prior year period on...

Boston Scientific (NYSE: BSX) has initiated a worldwide study that will evaluate the survival benefit of patients treated with the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD)...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2017 on Thursday, April 27,...

Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter...

Today, the National Institute for Health and Care Excellence (NICE) issued medical technology guidance recommending the use of Boston Scientific Corporation (NYSE: BSX) cardiac resynchronization...

Boston Scientific Corporation (NYSE: BSX) today announced the German District Court of Düsseldorf has determined that Edwards Lifesciences Corporation and its German subsidiary's Sapien 3™...

Boston Scientific Corporation (NYSE: BSX) will participate in the Barclays Global Healthcare Conference on March 15 in Miami Beach, Florida. Mike Mahoney, chairman and chief executive officer, and...

Boston Scientific Corporation (NYSE: BSX) today announced six finalists in its second annual Connected Patient Challenge, an open competition focused on turning big data into actionable...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen and Company 37th Annual Healthcare Conference on Tuesday, March 7, 2017 in Boston. Dan Brennan, executive vice...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2017 RBC Capital Markets Global Healthcare Conference on Thursday, February 23, 2017 in New York. Dan Brennan,...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.191 billion during the fourth quarter ended December 31, 2016. This represents growth of 11 percent compared to the prior year...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the LEERINK Partners 6th Annual Global Healthcare Conference on February 15, in New York. Susie Lisa, vice president,...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter ended December 31, 2016 on Thursday, February 2, 2017, at 8:00 a.m....

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 in San Francisco. Mike Mahoney, chairman and...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of certain manufacturing assets and capabilities of the Neovasc, Inc., (NASDAQ: NVCN) (TSX: NVC) advanced...

MARLBOROUGH, Mass., December 5, 2016 — Boston Scientific (NYSE: BSX) has been recognized for the third consecutive year as a “Best Place to Work” by the Human Rights Campaign Foundation. The...

Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire certain manufacturing assets and capabilities of the Neovasc, Inc., (NASDAQ: NVCN) (TSX: NVC) advanced...